A detailed history of Morgan Stanley transactions in Uni Qure N.V. stock. As of the latest transaction made, Morgan Stanley holds 1,518,228 shares of QURE stock, worth $6.77 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,518,228
Previous 1,759,818 13.73%
Holding current value
$6.77 Million
Previous $11.9 Million 33.74%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$4.82 - $6.93 $1.16 Million - $1.67 Million
-241,590 Reduced 13.73%
1,518,228 $7.89 Million
Q4 2023

Feb 13, 2024

SELL
$5.63 - $8.27 $5.19 Million - $7.62 Million
-921,591 Reduced 34.37%
1,759,818 $11.9 Million
Q3 2023

Nov 15, 2023

BUY
$6.71 - $11.83 $9.49 Million - $16.7 Million
1,413,959 Added 111.56%
2,681,409 $18 Million
Q2 2023

Aug 14, 2023

BUY
$11.12 - $22.2 $914,820 - $1.83 Million
82,268 Added 6.94%
1,267,450 $14.5 Million
Q1 2023

May 15, 2023

BUY
$18.7 - $23.07 $2.32 Million - $2.86 Million
123,989 Added 11.68%
1,185,182 $23.9 Million
Q4 2022

Feb 14, 2023

BUY
$18.12 - $27.32 $1.37 Million - $2.06 Million
75,429 Added 7.65%
1,061,193 $24.1 Million
Q3 2022

Nov 14, 2022

SELL
$16.98 - $25.54 $5.8 Million - $8.72 Million
-341,409 Reduced 25.72%
985,764 $18.5 Million
Q2 2022

Oct 27, 2022

SELL
$13.15 - $20.45 $618,128 - $961,272
-47,006 Reduced 3.42%
1,327,173 $24.7 Million
Q2 2022

Aug 15, 2022

SELL
$13.15 - $20.45 $618,128 - $961,272
-47,006 Reduced 3.42%
1,327,173 $24.7 Million
Q1 2022

Oct 27, 2022

BUY
$14.54 - $21.5 $683,467 - $1.01 Million
47,006 Added 3.54%
1,374,179 $24.8 Million
Q1 2022

May 13, 2022

BUY
$14.54 - $21.5 $1.93 Million - $2.85 Million
132,418 Added 10.66%
1,374,179 $24.8 Million
Q4 2021

Feb 14, 2022

BUY
$20.24 - $36.01 $19.1 Million - $34 Million
944,932 Added 318.34%
1,241,761 $25.8 Million
Q3 2021

Nov 15, 2021

BUY
$26.01 - $38.22 $7.72 Million - $11.3 Million
296,829 New
296,829 $9.5 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $208M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.